Importantly, our proposed model provides a plausible mechanistic explanation for the results of a recently published clinical study (Marquis et al., 2018) with more than 350 AML patients who were treated with TOP2 poisons in combination with the DNA synthesis inhibitor cytarabine (Ara‐C) as first‐line combination therapy. The gene discussed is TOP2A; the disease is acute myeloid leukemia.